Atria Wealth Solutions Inc. Sells 1,900 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Atria Wealth Solutions Inc. lowered its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 21.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,769 shares of the company’s stock after selling 1,900 shares during the period. Atria Wealth Solutions Inc.’s holdings in TransMedics Group were worth $422,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue acquired a new stake in shares of TransMedics Group in the 3rd quarter worth about $2,560,000. New York State Teachers Retirement System bought a new stake in TransMedics Group during the 3rd quarter worth approximately $1,217,000. Farther Finance Advisors LLC raised its stake in shares of TransMedics Group by 187.0% in the third quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of TransMedics Group by 48.2% in the third quarter. Harbor Capital Advisors Inc. now owns 8,964 shares of the company’s stock valued at $1,407,000 after purchasing an additional 2,916 shares in the last quarter. Finally, Amalgamated Bank boosted its position in shares of TransMedics Group by 777.4% during the third quarter. Amalgamated Bank now owns 9,774 shares of the company’s stock valued at $1,535,000 after buying an additional 8,660 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Trading Down 2.2 %

NASDAQ:TMDX opened at $72.12 on Friday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The firm’s 50 day moving average is $67.52 and its 200 day moving average is $102.22. The stock has a market capitalization of $2.42 billion, a PE ratio of 76.72 and a beta of 2.12.

Analyst Ratings Changes

A number of equities research analysts recently commented on TMDX shares. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Canaccord Genuity Group lowered their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Robert W. Baird cut their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, TD Cowen cut their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.